Apelian David 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Mar 16, 2018
Insider Transaction Report
Form 4
Apelian David
Director
Transactions
- Award
Stock Option (Right to Buy)
2018-03-14+37,000→ 37,000 totalExercise: $9.50Exp: 2028-03-13→ Common Stock (37,000 underlying)
Footnotes (1)
- [F1]The option vests in equal monthly installments over 48 months measured from March 14, 2018 subject to Reporting Person's continuous service status as of each such date.